Low Dose Leadelitamide in Myeloma

The Europeans were very cautious about this. They wanted to test low dose leadelitamide five milligrams per day, every day is one through 28. And what they showed was that those who respond to leadelitamide have a quite a favorable survival compared to those who were exposed to placebo. There was no increase in AML in the patient studied. The TP-3 clones seem to decrease, but it seemed to be extremely useful at this low dose and no important side effects. This last abstract from Dr. Zydin, my colleague from Yale, is really a trials in progress. He wants to see if you can replace ASO-VENT, or at least